============================================================
QUALITATIVE ERROR ANALYSIS REPORT
Generated on: 2025-08-21 14:53:50
Model: GPT-4o
Dataset: HIV
============================================================

1. BASIC PERFORMANCE METRICS:
   Accuracy: 0.948
   Precision: 0.919
   Sensitivity: 0.982
   F1-Score: 0.950
   Total samples: 11302
   TP: 5551, TN: 5163, FP: 488, FN: 100

2. SMILES COMPLEXITY ANALYSIS:
   False Positives: 488 cases
     Avg combined SMILES length: 114.4 ± 101.5
   False Negatives: 100 cases
     Avg combined SMILES length: 149.6 ± 75.9
   True Positives: 5551 cases
     Avg combined SMILES length: 131.5 ± 62.4
   True Negatives: 5163 cases
     Avg combined SMILES length: 113.4 ± 69.4

3. GENE TARGET COMPLEXITY ANALYSIS:
   False Positives: 488 cases
     Avg combined gene targets: 8.3 ± 11.8
   False Negatives: 100 cases
     Avg combined gene targets: 5.2 ± 4.6
   True Positives: 5551 cases
     Avg combined gene targets: 6.8 ± 9.4
   True Negatives: 5163 cases
     Avg combined gene targets: 5.2 ± 10.9

4. ORGANISM PATTERN ANALYSIS:
   Top false positives organism pairs:
     Humans - Humans: 393 cases
     Escherichia coli (strain K12) - Humans: 13 cases
     Humans - Escherichia coli (strain K12): 8 cases
     Humans - Human immunodeficiency virus 1: 7 cases
     Humans - Escherichia coli: 5 cases
   Top false negatives organism pairs:
     Human immunodeficiency virus 1 - Humans: 43 cases
     Humans - Humans: 23 cases
     Human immunodeficiency virus 1 - Escherichia coli (strain K12): 12 cases
     HBV-F - Humans: 12 cases
     Humans - Escherichia coli (strain K12): 4 cases

5. MOST PROBLEMATIC DRUGS:
   Cemiplimab: 1.000 error rate
     (1/1 errors: 1 FP, 0 FN)
   Eslicarbazepine acetate: 1.000 error rate
     (2/2 errors: 2 FP, 0 FN)
   Diroximel fumarate: 1.000 error rate
     (2/2 errors: 2 FP, 0 FN)
   Icosapent: 1.000 error rate
     (1/1 errors: 1 FP, 0 FN)
   Romiplostim: 1.000 error rate
     (2/2 errors: 2 FP, 0 FN)
   Azelastine: 1.000 error rate
     (1/1 errors: 1 FP, 0 FN)
   Emicizumab: 1.000 error rate
     (1/1 errors: 1 FP, 0 FN)
   Brexpiprazole: 1.000 error rate
     (1/1 errors: 1 FP, 0 FN)
   Abatacept: 1.000 error rate
     (2/2 errors: 2 FP, 0 FN)
   Alemtuzumab: 1.000 error rate
     (2/2 errors: 2 FP, 0 FN)

6. SPECIFIC ERROR EXAMPLES:
   False Positives (predicted interaction, but no real interaction):
     1. Tocilizumab + Tazobactam
        Organisms: Humans - Escherichia coli
        Gene targets: 1 - 2
     2. Rilmenidine + Cemiplimab
        Organisms: Humans - Humans
        Gene targets: 1 - 1
     3. Prednisolone acetate + (R)-Rolipram
        Organisms: Humans - Humans
        Gene targets: 1 - 2
     4. Tafamidis + Eslicarbazepine acetate
        Organisms: Humans - Humans
        Gene targets: 1 - 1
     5. Diroximel fumarate + S-(Methylmercury)-L-Cysteine
        Organisms: Humans - Humans
        Gene targets: 1 - 1
   False Negatives (missed real interactions):
     1. Abacavir + Dutasteride
        Organisms: Humans - Humans
        Gene targets: 2 - 2
     2. Abacavir + Levomenthol
        Organisms: Humans - Humans
        Gene targets: 2 - 13
     3. Abacavir + Riboflavin
        Organisms: Humans - Humans
        Gene targets: 2 - 3
     4. Atazanavir + Thiamine
        Organisms: Human immunodeficiency virus 1 - Humans
        Gene targets: 1 - 1
     5. Darunavir + Riboflavin
        Organisms: Human immunodeficiency virus 1 - Humans
        Gene targets: 1 - 3

7. SUMMARY INSIGHTS:
   - Model tends to over-predict interactions (more false positives than false negatives)
   - High sensitivity but lower precision - good at catching interactions but with some false alarms

Report generation completed successfully.
============================================================
